

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Odagiri K, Mizuta I, Yamamoto M, Miyazaki Y, Watanabe H, Uehara A	Waist to height ratio is an independent predictor for the incidence of chronic kidney disease	PLoS One	9	e88873	2014
Tamura Y, Izumiyama- Shimomura N, Kimbara Y, Nakamura KI, Ishikawa N, Aida J, Chiba Y, Mori S, Arai T, Aizawa T, Araki A, Takubo K, Ito H	Beta Cell Telomere Attrition in Diabetes: Inverse Correlation Between HbA1c and Telomere Length.	J Clin Endocrinol Metab		in press	2014
Kobayashi K, Yokoh H, Sato Y, Takemoto M, Uchida D, Kanatsuka A, Kuribayashi N, Terano T, Hashimoto N, Sakurai K, Hanaoka H, Ishikawa K, Onishi S, Yokote K	Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with $\alpha$ -glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-inferiority trial.	Diabetes Obes Metab.	27	doi: 10.1111/ dom.12264	2014
Hayashi T, Kotani H, Yamaguchi T, Taguchi K, Iida M, Ina K, Maeda M, Kuzuya M, Hattori Y, Ignarro L. J.	Endothelial cellular senescence is inhibited by liver X receptor activation with an additional mechanism for its atheroprotection in diabetes.	Proc Nat Acad Sci USA	111	1168-1173	2014

#### IV. 研究成果の刊行物・別冊

**ORIGINAL INVESTIGATION**

**Open Access**

# Metabolic predictors of ischemic heart disease and cerebrovascular attack in elderly diabetic individuals: difference in risk by age

Toshio Hayashi<sup>1\*</sup>, Atsushi Araki<sup>2</sup>, Seinosuke Kawashima<sup>3</sup>, Hirohito Sone<sup>4</sup>, Hiroshi Watanabe<sup>5</sup>, Takashi Ohru<sup>6</sup>, Koutaro Yokote<sup>7</sup>, Minoru Takemoto<sup>7</sup>, Kiyoshi Kubota<sup>8</sup>, Mitsuhiko Noda<sup>9</sup>, Hiroshi Noto<sup>9</sup>, Koichiro Ina<sup>1</sup>, Hideki Nomura<sup>1,10</sup> and on behalf of Japan CDM group

## Abstract

**Background:** High LDL-cholesterol (LDL-C) and glucose levels are risk factors for ischemic heart disease (IHD) in middle-aged diabetic individuals; however, the risk among the elderly, especially the very elderly, is not well known. The aim of this study was to identify factors that predict IHD and cerebrovascular attack (CVA) in the elderly and to investigate their differences by age.

**Methods:** We performed a prospective cohort study (Japan Cholesterol and Diabetes Mellitus Study) with 5.5 years of follow-up. A total of 4,014 patients with type 2 diabetes and without previous IHD or CVA (1,936 women; age  $67.4 \pm 9.5$  years, median 70 years; <65 years old,  $n = 1,261$ ; 65 to 74 years old,  $n = 1,731$ ; and  $\geq 75$  years old,  $n = 1,016$ ) were recruited on a consecutive outpatient basis from 40 hospitals throughout Japan. Lipids, glucose, and other factors related to IHD or CVA risk, such as blood pressure (BP), were investigated using the multivariate Cox hazard model.

**Results:** One hundred fifty-three cases of IHD and 104 CVAs (7.8 and 5.7/1,000 people per year, respectively) occurred over 5.5 years. Lower HDL-cholesterol (HDL-C) and female gender were correlated with IHD in patients  $\geq 75$  years old (hazard ratio (HR):0.629,  $P < 0.01$  and 1.132,  $P < 0.05$ , respectively). In contrast, systolic BP (SBP), HbA1C, LDL-C and non-HDL-C were correlated with IHD in subjects <65 years old ( $P < 0.05$ ), and the LDL-C/HDL-C ratio was correlated with IHD in all subjects. HDL-C was correlated with CVA in patients  $\geq 75$  years old (HR: 0.536,  $P < 0.01$ ). Kaplan-Meier estimator curves showed that IHD occurred more frequently in patients <65 years old in the highest quartile of the LDL-C/HDL-C ratio. In patients  $\geq 75$  years old, IHD and CVA were both the most frequent among those with the lowest HDL-C levels.

**Conclusions:** IHD and CVA in late elderly diabetic patients were predicted by HDL-C. LDL-C, HbA1C, SBP and non-HDL-C are risk factors for IHD in the non-elderly. The LDL-C/HDL-C ratio may represent the effects of both LDL-C and HDL-C. These age-dependent differences in risk are important for developing individualized strategies to prevent atherosclerotic disease.

**Trial registration:** UMIN-CTR, UMIN00000516

**Keywords:** Elderly, Diabetes mellitus, Cardiovascular diseases, HDL-C, LDL-C/HDL-C ratio

\* Correspondence: hayashi@med.nagoya-u.ac.jp

<sup>1</sup>Department of Geriatrics, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya, Japan

Full list of author information is available at the end of the article

## Introduction

Type 2 diabetes mellitus, dyslipidemia and aging are independent risk factors for cardiovascular diseases, such as ischemic heart disease (IHD). Within diabetic individuals, lipids, especially LDL-cholesterol (LDL-C), blood pressure (BP), and diabetic control are risk factors for IHD [1-4]. For example, the United Kingdom Prospective Diabetes Study (UKPDS) showed the importance of BP, lipids, and diabetic control in the prevention of IHD in newly diagnosed diabetic individuals (mean age 53 years, range 25–65 years), and subsequent studies have confirmed these findings [1,2]. However, the risk factors for IHD or cerebrovascular attack (CVA) in elderly diabetic individuals (older than 65 years), particularly in late elderly diabetic individuals (older than 75 years), have not been identified.

In Western countries, the evidence suggests that middle-aged diabetic individuals have an IHD risk similar to that of non-diabetic patients who have experienced a myocardial infarction, and the guidelines for diabetes treatment recommend that the LDL-C level should be less than 100 mg/dl, which is similar to the recommendation for the secondary prevention of myocardial infarction [5,6]. However, it is unknown whether the same risk exists for elderly diabetic individuals. Additionally, many guidelines recommend strict control of LDL-C levels to prevent atherothrombotic diseases, especially in diabetic patients, yet recommend the same HDL-cholesterol (HDL-C; 40 mg/dl) and triglyceride (TG; 150 mg/dl) levels as for non-diabetic individuals [5-7]. There are few reports on the absolute risk conferred by HDL-C and TG in elderly diabetic patients.

Additionally, diabetes can either develop in the elderly or continue through old age after an earlier onset. Even in elderly individuals without diabetes, postprandial hyperglycemia occurs because of a delay in insulin secretion in response to feeding and may contribute to an increase in the number of elderly diabetic patients [8]. The International Diabetes Federation (IDF) reports that the number of diabetic patients increased from 30 million in 1987 to 246 million in 2007 (7% of adults) and speculates that it will increase to 380 million by 2027 [9]. In Japan, 30% of diabetic individuals were elderly in 1997 (13% of the elderly suffered from diabetes mellitus), which increased to 40% in 2007 (17% of the elderly). Furthermore, individuals older than 75 (13 million) comprise over 10% of the total population. However, no large-scale investigations have focused on type 2 diabetes mellitus in the elderly, especially in the late elderly, or those older than 75 [10]. Thus, evaluating the metabolic predictors of atherosclerotic diseases, such as IHD and CVA, in elderly diabetic individuals is important. For these reasons, we organized the Japan Cholesterol and Diabetes Mellitus Study (JCDM) to evaluate which factors

can predict IHD or CVA in diabetic patients, including the elderly. Our elderly sample population included 1,016 late elderly, who were older than 75 and performed independent daily life activities at outpatient clinics [11].

## Materials and methods


### Subjects

The JCDM is a prospective, cohort study that consists of 4,014 Japanese diabetic individuals from 40 hospitals throughout Japan who were recruited on a consecutive outpatient basis between September 2004 and March 2005 (1,936 women; mean age  $67.4 \pm 9.5$  years, median age 70 years; Figure 1) [11]. The JCDM protocol, which is in accordance with the provisions of the Declaration of Helsinki, received ethical approval from the institutional review boards of all the participating institutes. Written informed consent was obtained from all patients. The criteria from the American Diabetes Association for type 2 diabetes mellitus diagnosis were used [6]. Patients with previous IHD (myocardial infarction, unstable angina pectoris, angioplasty, or bypass grafting) or CVA (recent stroke with admission within the past 24 months) were excluded, as were patients whose medical records concerning plasma lipids (TG, HDL-C and total cholesterol or LDL-C) were not provided. The other exclusion criteria were a history or complication of serious heart disease (e.g., severe arrhythmia, heart failure, cardiomyopathy, valvular disease, or congenital disease), serious hepatic or renal disease with admission within the past 24 months, malignant disease, intention to undergo surgery, any illness with a poor prognosis of less than one year, and judgment by the physician in charge that the patient was not suitable for the study.

At 24 months (2007), 92.3% of the enrolled patients were followed up, and 84.1% were followed up at 66 months (2010). Patients were divided into groups based on age at registration: younger than 65 (non-elderly,  $n = 1,267$ ), 65 to 74 years old (early elderly,  $n = 1,731$ ) and older than 75 (late elderly,  $n = 1,016$ ). These age categories are used frequently in Japan for the study of elderly patients and for health care insurance purposes [12].

### Outcome measurements

The primary endpoints were the incidence of IHD and CVA, specifically fatal and non-fatal myocardial infarction and other non-fatal events, including unstable angina pectoris, angioplasty, stenting, coronary artery bypass grafting and stroke. Detailed definitions of each event are shown below. Transient ischemic attacks were included only if definite focal lesions from the attack were confirmed by head CT or MRI.



### Risk factor assessment

Metabolic factors, such as the levels of plasma lipids, fasting plasma glucose (FPG), and HbA1C and BP, were measured at enrollment. The serum LDL-C level was calculated using the Friedewald equation, except in the case of a TG level higher than 400 mg/dl, in which case the LDL-C data were recorded as 'missing.' Information about previous history of IHD and stroke and findings from a 12-lead ECG were obtained for all patients to assess cardiovascular disease at baseline. The study was approved by the institutional review boards and by the safety monitoring board every year. The organizing committee confirmed all cardiovascular events annually. The guidelines of the Japan Atherosclerosis Society (2002) state that the LDL-C level should be less than 120 mg/dl and that the HDL-C level should be higher than 40 mg/dl in diabetic individuals; these clinical guidelines were likely followed by the physicians who were treating these patients at the time of the study [12].

### Statistical methods

The results are presented as the means  $\pm$  SD. All statistical analyses were performed using JMP software (SAS Institute, Inc., Cary, NC). The incidences of IHD and CVA were analyzed in relation to the aforementioned risk factors. Cox multivariate regression analyses were

used. Because LDL-C/HDL-C interacts strongly with LDL-C and HDL-C and because non-HDL-C interacts with triglyceride and LDL-C, we analyzed non-HDL-C and LDL-C/HDL-C separately. In other words, common factors (gender, age, duration of diabetes, HbA1C, FPG, systolic BP (SBP), and diastolic BP (DBP)), TG, LDL-C and HDL-C were analyzed first. Then, non-HDL-C and common factors were analyzed. Finally, LDL-C/HDL-C, common factors and TG were analyzed. Values of  $P < 0.05$  were considered statistically significant.

**Definition of major events.** Major events such as IHD and CVA were defined as follows.

1. Definite fatal and nonfatal myocardial infarction (1 or more of the following criteria must be met):
  - a) Diagnostic ECG at the time of the event.
  - b) Ischemic cardiac pain (and/or unexplained acute left ventricular failure) and diagnostic enzyme levels.
  - c) Ischemic cardiac pain and/or unexplained acute left ventricular failure with both equivocal enzyme levels and equivocal ECG.
  - d) Diagnostic enzyme levels and equivocal ECG.
  - e) Angiographic evidence of major artery occlusion with appropriate ventriculographic wall motion

abnormality where a previous angiogram showed no such abnormality.

f) Postmortem examination.

2. Angina pectoris (stable or unstable, both of the following criteria must be met):

a) Ischemic cardiac pain relieved by nitrates.

b) Equivocal ECG.

3. Ischemic stroke (1 of the following conditions must be met):

a) Rapid onset of focal neurologic deficit lasting at least 24 h or leading to death, plus evidence from neuroimaging (computed tomography or magnetic resonance imaging) showing cerebral/cerebellar infarction or no abnormality, or postmortem examination showing cerebral and/or cerebellar infarction.

b) Rapid onset of global neurological deficit (e.g., coma) lasting at least 24 h or leading to death, plus evidence from neuroimaging showing infarction, or postmortem examination showing infarction.

c) Focal neurological deficit (mode of onset uncertain) lasting at least 24 h or leading to death, plus evidence from neuroimaging showing infarction, or postmortem examination showing infarction.

4. Primary intracerebral hemorrhage (1 of the following conditions must be met):

a) Rapid onset of focal neurological deficit lasting at least 24 h or leading to death, plus neuroimaging or postmortem examination showing primary intracerebral and/or cerebellar hemorrhage.

b) Rapid onset of global neurologic deficit (e.g., coma) lasting at least 24 h or leading to death, plus evidence from neuroimaging or postmortem examination showing primary intracerebral and cerebellar hemorrhage.

c) Focal neurologic deficit (mode of onset uncertain) lasting at least 24 h or leading to death, plus evidence from neuroimaging or postmortem examination showing primary intracerebral and/or cerebellar hemorrhage.

In this study, intracerebral hemorrhage was not included in the variable CVA (stroke) because its pathophysiology is reported to be different from other atherosclerotic diseases, such as stroke and ischemic heart disease.

## Results

### Subject characteristics

Table 1 presents the following subject characteristics: plasma lipid levels, including LDL-C, TG, and HDL-C; other relevant metabolic measures, such as HbA1C level, FPG level, and SBP and DBP; the duration of diabetes; and the number of patients who were prescribed medications for hypertension, dyslipidemia, and diabetes, as well as the type, upon enrollment. The levels of HbA1C and HDL-C were not different by age group. Dyslipidemia was observed in 79.1% of patients, and anti-hyperlipidemic drugs were prescribed for 57.3% of the total population, of which 83% were HMG-CoA reductase inhibitors (statins). Statins and insulin were prescribed with the same frequency for late elderly patients as for non-elderly patients. Insulin and oral agents for diabetes treatment were prescribed for 23.9% and 70.5% of the late elderly and non-elderly individuals, respectively. Agents for hypertension and diabetes were prescribed more often in late elderly patients than in non-elderly patients. There were also significant differences in several other factors among the age groups.

### IHD and CVA incidence

One hundred fifty-three cases of IHD and 104 CVAs occurred during the 5.5 years of the study, which represented incidences of 7.9 and 5.6 per 1,000 patients per year, respectively. The number of deaths was 59 (3.1/1,000 patient-years) over the 5.5 years (Table 2, Figure 1).

The relationships between IHD or CVA and the background factors, such as LDL-C level, in each age group were analyzed by Cox proportional regression analyses (Table 2, Figure 2).

As described in the methods, non-HDL-C and LDL-C/HDL-C were analyzed separately from other lipids, such as LDL-C and triglyceride or HDL-C. However, significant factors were the same in total and in each generation group, although the HR and CI of common factors (gender, age, duration of diabetes, HbA1C, FPG, systolic BP (SBP), and diastolic BP (DBP)) were slightly different in each (data not shown for the HR and CI of common factors in the analyses of non-HDL-C and LDL-C/HDL-C).

In the total patient population, the levels of HbA1C, LDL-C, and HDL-C, and the LDL-C/HDL-C ratio were significantly related to IHD, and only the HDL-C level was significantly related to a CVA. The HbA1C level, SBP, and LDL-C levels were significantly correlated with IHD in patients less than 65 years old, while the variables female gender, short duration of diabetes and HDL-C level were correlated with IHD in patients older than 75. Because the non-HDL-C level and the LDL-C/HDL-C ratio have been proposed as markers representing all types of lipids, we included them in a separate model (excluding LDL-C, triglyceride and HDL-C levels

**Table 1 Basic patient profile**

n = 4014	Total		<65 years		65-74 years		≥75 years		P1	Male		Female		P2
	n = 4014		n = 1267		n = 1731		n = 1016			n = 2078		n = 1936		
	Mean	SD	Mean	SD	Mean	SD	Mean	SD		Mean	SD	Mean	SD	
Gender (% male)	51.2	53.1	49.8	49.9	*	100.0	0	-						
Age (yrs,mean/median)	67.9/70	2.0	56.5/58	7.0	70.0/70	2.7	78.8/78	3.5	-	67.0/69	10.0	69.7/70	8.7	**
Duration of DM (months)	177.9	70.0	156.3	64.5	186.1	101.2	190.7	104.3	***	191.6	108.9	169.8	79.7	**
HbA1C (%)	7.70	0.80	7.74	1.38	7.72	1.18	7.62	1.14	0.17	7.61	1.25	7.79	1.20	**
FPG (mg/dl)	149.8	30.3	157.9	53.2	146.4	45.7	145.4	42.0	**	150.9	48.8	146.9	44.9	0.17
SBP (mmHg)	137.3	11.7	133.1	17.3	135.3	16.8	146.0	17.5	**	133.8	17.2	135.9	17.1	*
DBP (mmHg)	74.0	7.3	76.1	11.8	73.5	10.6	72.3	10.7	***	74.5	11.1	73.3	10.9	*
TG (mg/dl)	138.2	53.8	159.4	156.3	128.5	82.0	128.4	73.0	***	142.9	126.3	131.3	83.7	0.18
LDL-C (mg/dl)	118.2	21.3	121.6	33.8	117.6	32.1	115.0	29.3	*	115.0	31.8	121.2	31.4	**
HDL-C (mg/dl)	55.8	10.7	54.8	15.6	55.4	15.5	57.7	15.8	0.38	53.42	15.4	56.78	15.7	**
Non-HDL-C (mg/dl)	145.8	23.4	153.2	40.3	143.3	35.5	141.0	31.8	*	143.6	36.9	147.5	35.6	*
LDL-C/HDL-C	2.31	0.74	2.41	1.17	2.31	1.21	2.27	0.88	*	2.33	0.95	2.33	1.28	0.21
Agents for HT (%)	55.5		49.3		56.0		62.3		**	48.5		62.0		***
ACEI/ARB	39.7		36.9		40.4		41.9		0.65	35.8		43.4		*
CCB	41.2		32.4		43.7		52.6		0.31	36.0		46.5		*
Others	28.3		22.5		31.8		31.4		0.69	28.9		26.7		0.66
Agents for DL (%)	57.3		63.8		54.8		52.6		**	52.1		60.1		***
Strong statins	29.6		31.1		28.3		25.4		0.36	29.7		29.5		0.89
Classical statins	53.3		47.0		58.0		61.6		0.11	51.9		55.0		0.23
Fibrates	8.9		12.0		6.5		6.8		0.13	9.8		7.9		0.18
Others	8.2		9.9		7.2		6.2		0.10	8.6		7.6		0.22
Agents for DM (%)	86.6		76.9		91.6		90.3		**	85.1		88.6		*
Insulin	23.9		24.4		24.6		21.7		0.42	28.0		32.4		*
Sulfonylurea	49.5		41.5		51.3		53.7		0.21	50.0		48.9		0.29
Others	26.1		34.6		21.4		24.5		0.19	26.0		22.0		*
IHD (/1000 year)	9.68		8.84		10.04		9.87		0.97	10.26		9.47		0.32
CVA (/1000 year)	6.78		4.45		7.44		7.56		0.21	7.02		5.72		0.27

P1: Differences in each factor among ages. P2: Differences in each factor between genders. HbA1C:NGSP, \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001.

to avoid the interactive effect on non-HDL-C, or excluding LDL-C and HDL-C levels for the LDL-C/HDL-C ratio). The non-HDL-C level was only correlated with IHD in patients younger than 65. The LDL-C/HDL-C ratio was significantly correlated with IHD in patients of all generations. Age and lower HDL levels were correlated with CVA in patients over 75 years old (Table 2, Figure 2). Subsequently, we evaluated the relationships with IHD and CVA according to the quartile categories for each age group by Kaplan-Meier estimator curves. The HDL-C level was inversely correlated with IHD and CVA, particularly in individuals over 75 (Figure 3). The LDL-C/HDL-C ratio tended to correlate with IHD in all individuals (Figure 3). For the variable current smokers, 6.8% of the total population of subjects smoked. By age category, 9.9, 6.7 and 3.8% of patients younger than 65, patients between 65 and 74, and patients older than 75

smoked, respectively. As the duration of diabetes is pretty long, number of present smokers is not many.

## Discussion

### Background and discussion points of the study


The numbers of diabetic elderly and their associated net medical costs have drastically increased in recent decades. The mean life expectancy is now approximately an additional 12 and 16 years at age 75 for males and females in Japan, respectively, although the average life span is 78.9 and 85.6 years, respectively. Consequently, the number of late elderly (individuals older than 75) exceeds 13 million, or 10% of the total Japanese population. Diabetes can either develop in the elderly or continue through old age after an earlier onset, and the numbers of diabetic elderly are increasing. In Japan, 55% of diabetic individuals were elderly in 2007, and

**Table 2 Risk factors for IHD and CVA by Cox multivariate models in each age group (IHD, upper; CVA, lower)**


n = 4014	Total (n = 4014)			<65 years (n = 1267)			65-74 years (n = 1731)			≥75 years (n = 1016)		
	Adjusted HR	95% CI	P	Adjusted HR	95% CI	P	Adjusted HR	95% CI	P	Adjusted HR	95% CI	P
<b>IHD</b>												
Gender (women vs. men)	1.103	0.972–1.268	0.197	1.044	0.967–1.073	0.456	1.085	0.978–1.210	0.101	<b>1.132</b>	<b>0.992–1.278</b>	<b>0.019*</b>
Age (per 10 years)	1.013	0.972–1.066	0.328	1.022	0.977–1.079	0.229	<b>1.054</b>	<b>1.002–1.106</b>	<b>0.049*</b>	1.005	0.871–1.139	0.682
Duration of Diabetes (months)	0.995	0.988–1.003	0.053	1.001	0.991–1.008	0.582	<b>0.993</b>	<b>0.985–0.999</b>	<b>0.033*</b>	<b>0.992</b>	<b>0.982–0.999</b>	<b>0.023*</b>
HbA1C (per 1%)	<b>1.171</b>	<b>1.001–1.356</b>	<b>0.047*</b>	<b>1.327</b>	<b>1.025–1.686</b>	<b>0.032*</b>	1.219	0.973–1.487	0.083	0.792	0.479–1.059	0.134
FPG (per 10 mg/dl)	1.004	0.997–1.008	0.432	1.005	0.996–1.013	0.355	1.004	0.997–1.009	0.592	0.999	0.987–1.007	0.761
SBP(per 10 mmHg)	1.008	0.995–1.021	0.186	<b>1.030</b>	<b>1.000–1.055</b>	<b>0.035*</b>	1.014	0.994–1.037	0.175	0.986	0.954–1.014	0.331
DBP(per 10 mmHg)	0.995	0.978–1.015	0.618	0.982	0.948–1.024	0.386	0.980	0.950–1.011	0.206	1.027	0.986–1.073	0.202
TG (quartile)	1.005	0.889–1.166	0.555	1.002	0.996–1.006	0.502	1.108	0.997–1.220	0.065	1.001	0.961–1.046	0.454
LDL-C (quartile)	<b>1.318</b>	<b>1.103–1.585</b>	<b>0.023*</b>	<b>1.571</b>	<b>1.128–2.524</b>	<b>0.016*</b>	1.050	0.932–1.176	0.112	1.156	0.998–1.309	0.054
HDL-C (quartile)	<b>0.751</b>	<b>0.611–0.917</b>	<b>0.005**</b>	0.828	0.646–1.017	0.072	0.987	0.966–1.008	0.204	<b>0.629</b>	<b>0.401–0.856</b>	<b>0.001**</b>
Non-HDL-C (quartile)	1.023	0.981–1.072	0.075	<b>1.025</b>	<b>1.001–1.121</b>	<b>0.044*</b>	1.073	0.982–1.161	0.086	0.941	0.791–1.102	0.621
LDL-C/HDL-C (quartile)	<b>1.583</b>	<b>1.298–1.945</b>	<b>0.001**</b>	<b>2.324</b>	<b>1.516–3.795</b>	<b>0.001**</b>	<b>1.359</b>	<b>1.028–1.824</b>	<b>0.021*</b>	<b>1.407</b>	<b>1.015–2.592</b>	<b>0.029*</b>
<b>CVA</b>												
Gender	1.164	0.985–1.296	0.351	1.014	0.897–1.240	0.655	1.208	0.896–1.526	0.112	0.953	0.912–1.012	0.063
Age	1.015	0.986–1.039	0.282	1.002	0.957–1.076	0.754	1.007	0.916–1.166	0.537	<b>1.103</b>	<b>1.002–1.217</b>	<b>0.048*</b>
Duration of Diabetes	0.998	0.992–1.001	0.206	1.003	0.987–1.017	0.709	0.996	0.989–1.001	0.096	0.999	0.991–1.005	0.818
HbA1C	1.001	0.790–1.214	0.128	1.019	0.691–1.401	0.814	0.997	0.855–1.222	0.569	0.928	0.822–1.010	0.059
FPG	1.005	0.995–1.005	0.803	1.003	0.990–1.018	0.741	1.002	0.995–1.008	0.592	0.998	0.986–1.008	0.711
SBP	1.009	0.993–1.024	0.276	1.024	0.988–1.055	0.185	1.015	0.992–1.037	0.206	0.989	0.957–1.018	0.458
DBP	0.998	0.978–1.020	0.846	0.995	0.958–1.046	0.831	0.981	0.948–1.016	0.278	1.024	0.978–1.074	0.317
TG	1.132	0.908–1.302	0.156	1.053	0.658–1.742	0.833	1.253	0.900–1.780	0.184	1.169	0.746–1.853	0.497
LDL-C	1.009	0.912–1.191	0.675	<b>1.005</b>	<b>1.001–1.100</b>	<b>0.047*</b>	1.015	0.892–1.136	0.714	0.997	0.982–1.012	0.631
HDL-C	<b>0.742</b>	<b>0.596–0.901</b>	<b>0.003**</b>	0.715	0.591–1.191	0.200	<b>0.750</b>	<b>0.494–1.000</b>	<b>0.049*</b>	<b>0.536</b>	<b>0.320–0.851</b>	<b>0.007**</b>
Non-HDL-C	0.981	0.945–1.019	0.206	<b>1.021</b>	<b>1.003–1.141</b>	<b>0.045*</b>	0.942	0.872–1.013	0.172	1.012	0.954–1.077	0.226
LDL-C/HDL-C	1.180	0.951–1.477	0.132	1.271	0.819–2.232	0.263	1.114	0.853–1.582	0.356	1.209	0.803–1.847	0.364

The top panels show the analyses of IHD for subjects aged <65 years (left), 65–74 years (middle) and ≥75 years (right). The lower panels show the incidence of CVA. Bold indicate statistically significant factors. Hazard ratios and 95% CIs are shown. The ratio of males to females was 1. As LDL-C/HDL-C interacts strongly with LDL-C and HDL-C, and non-HDL-C interacts triglyceride and LDL-C, analysis of non-HDL-C and LDL-C/HDL-C were separately shown in methods section.





**Figure 2 Risk factors for IHD and CVA by Cox multivariate models in representative age groups (IHD, Left; CVA, Right).** The upper panels show the analyses of IHD for those younger than 65 years old (Left) and CVA for those younger than 65 years old (Right). The lower panels show the analyses of IHD (Left) and CVA (Right) for those equal to or older than 75 years. HR stands for Hazard Ratio (vertical bar shows 1). Bold characters indicate statistically significant factors. The right side of each figure shows Hazard Ratios and 95% CIs. Because LDL-C/HDL-C interacts strongly with LDL-C and HDL-C and because non-HDL-C interacts with triglyceride and LDL-C, we analyzed non-HDL-C and LDL-C/HDL-C separately. In other words, common factors (gender, age, duration of diabetes, HbA1C, FPG, systolic BP (SBP), and diastolic BP (DBP)), TG, LDL-C and HDL-C were analyzed. Then, non-HDL-C and common factors were analyzed. Finally, LDL-C/HDL-C, common factors and TG were analyzed.



approximately 25% were late elderly. These trends are spreading across the world, mainly in developed countries; however, the risk factors for IHD or CVA in late elderly diabetic individuals have not been identified. In the late elderly, atherosclerotic diseases, such as IHD and CVA, are a more frequent cause of death than malignancy. In Canada, diabetic patients are reported to suffer myocardial infarction approximately 14 years earlier than patients without diabetes [13]. However, there is little evidence on the risk and preventive factors for IHD or CVA in the diabetic elderly, and there are no reports on the late elderly [14,15].

Therefore, we organized this study as one of the largest attempts to examine IHD and CVA in middle-aged to elderly diabetic individuals. We defined the age categories as follows: 1) non-elderly: younger than 65, 2) early elderly: from 65 to 74, and 3) late elderly: equal to or older than 75. Sixty-five is usually defined as the threshold for being elderly worldwide [13,16], and 75 is the beginning of the late elderly age in Japan, as defined by health insurance and care insurance systems and the Japan Geriatric Society [12].

#### The effect of age on IHD and CVA risk factors

One hundred fifty-three cases of IHD and 104 CVAs occurred, which represents 7.8 and 5.7/1,000 people per

year, respectively, over this 5.5-year study, although we defined stroke strictly and excluded cerebral and subarachnoid hemorrhages from this definition. IHD occurs 2 to 3 times more frequently in diabetic individuals compared to the normal Japanese population, and CVA also occurs more frequently in diabetic individuals [17]. The prevalence of IHD and CVA is slightly higher than reported in previous Japanese diabetic studies because we targeted relatively older diabetic individuals [16,17]. However, even in diabetic individuals, the combined frequency of IHD and stroke was slightly lower in the Japanese population than among Caucasians [18].

To look for the candidate metabolic markers that may predict IHD and CVA in various age groups, Cox regression analyses were performed. The analyses showed that higher HbA1C and LDL-C levels, SBP and non-HDL-C were significantly correlated with the occurrence of IHD in subjects <65 years old, which is similar to previous reports [14-16]. The ratio of males/females was not significantly different between patients <65, patients between 65 and 74, and patients ≥75. A relation between diabetes and ischemic stroke was reported. Patients (59.8 ± 7.2 y.o.) having a history of coronary heart disease with diabetes mellitus exhibited a 2.29-fold increased risk for stroke or TIA during the 4.8- to 8.1-year follow-up period than patients without diabetes. Impaired fasting

glucose and hypertension were predictors, while HDL-C was not. These results are fairly consistent with those of the younger patients group (< 65 y.o.) in the present study [19].

In patients  $\geq 75$  y.o., a lower HDL-C level was correlated with IHD and CVA. This is a novel finding of the present study. Few data are available on the relationship between elderly type 2 diabetic patients and CVA, particularly among the late elderly [16-18,20]; therefore, the finding of the importance of HDL-C in CVA in the late diabetic elderly may be important. The Kaplan-Meier estimator curves, which are shown in Figure 1, support these findings.

Thus, a lower HDL-C level is an important risk factor for both IHD and CVA among the late elderly diabetic patients in this study. Although the protective effects of higher HDL-C on IHD in the non-elderly are known, the effects on IHD among late elderly diabetics are not known [21]. The CVA and IHD incidences in the late elderly may decrease to the levels found in middle-aged cohorts if higher HDL-C has protective effects on late elderly diabetic individuals and if their levels are easily increased. There are few agents available to increase HDL-C levels, except exercise, and adequate exercise or bodily movement may be necessary even in the elderly. The low HDL-C level may be related to low levels of physical activity in the elderly, which could influence a CVA in many ways that are separate from the HDL-C level. Atherosclerosis is an inflammatory disorder, and HDL-C may preserve endothelial function by increasing endothelial NO [22].

For LDL-C, three large-scale clinical studies on dyslipidemia, which included participants who were up to 75 or 80 years of age, are available [23-25]. Although these studies reported that the reduction in LDL-C by statins decreases IHD (including in diabetic people), the effects were weak in the elderly compared with those in the non-elderly (e.g., Prosper reported that pravastatin, a water-soluble statin, induced a 16% decrease in IHD without any effect on CVA in elderly patients compared to a 21% decrease in non-elderly patients). These data suggest that simply controlling LDL-C may not prevent IHD or CVA in the elderly. There are also no large observational studies on the diabetic elderly older than 75 [26,27]. For example, the international FIELD study analyzed approximately 10,000 patients up to the age of 75 years, with a mean age 63 years [26], and the Swedish NDR-study analyzed 18,673 patients up to 70 years old, with a mean age of 60 years [27]. These large observational studies, analyzing all patients, found LDL-C, non-HDL-C, HDL-C, triglycerides and ratios of LDL-C/HDL-C and total-cholesterol/HDL-C to be significant risk factors for IHD. These data are consistent with our data on participants younger than 65, although those

observational studies did not include patients older than 75. To lower LDL-C levels, 57% of the patients in our study had already been prescribed anti-dyslipidemic agents, of which 83% were statins. The average LDL-C level was 120 mg/dl, which matches the guidelines of the Japan atherosclerosis society but not that of the American Heart Association or IDF (100 mg/dl). Although doses and types of anti-dyslipidemic agents were changed often during the study, their effects other than LDL reduction (pleiotropic effects) cannot be evaluated yet.

Our study shows the importance of the LDL-C/HDL-C ratio as well as HDL-C and LDL-C levels, although the strength of these effects is different based on age. The LDL-C/HDL-C ratio was associated with IHD, which may represent the effect of LDL-C levels in the non-elderly and HDL-C levels in the elderly [28]. The non-HDL-C level and the total cholesterol/HDL-C ratio are also proposed markers of atherosclerotic diseases [29,30]. The non-HDL-C level was associated with IHD only among those younger than 65, and the total cholesterol/HDL-C ratio was not significantly associated with IHD (data not shown). We believe that these data are consistent with previous data from non-elderly diabetic individuals because the non-HDL-C level is a reflection of the effect of triglyceride levels, and hyper-triglyceridemia, complicated with metabolic syndrome, occurs more often in non-elderly than in elderly people.

Emerging Risk Factors Collaboration analysis showed the association of non-HDL-C with IHD and CVA. However, in this study, it was associated with CVA only in those younger than 65. The two studies are different in that 1) our cohort consisted only of diabetic patients; 2) in the Collaboration analysis, the mean age was 56.6 y.o., compared to 67.4 y.o. in our study; and 3) in the Collaboration analysis, almost all of the patients were North American or European, whereas our study was Japanese patients only. In the elderly, triglycerides are usually lower than in younger individuals, and non-HDL-C represents triglyceride.

A 1-mg/dl change in HDL-C and/or a 2-mg/dl change in LDL-C reflect a 2% change in the risk for atherosclerotic diseases, and this may be partially consistent within our diabetic elderly study [31]. The LDL-C/HDL-C ratio may reflect the direct effects of both LDL-C and HDL-C levels, which may affect or interact with the progression of atherosclerosis and thrombosis formation more than other lipids, such as chylomicrons and chylomicron remnants, which are represented by the non-HDL-C level or the TC/HDL-C ratio. The fact that elderly individuals have different risk factors than younger individuals could be associated with genetic protection from such events or an accumulation of personal habits that may provide the elderly with protection. For example, differences in single nucleotide polymorphisms (SNP)

may be related to the severity of atherosclerosis and, subsequently, to the different effects of predictors by age and should be evaluated in the future [32].

Interestingly, impaired fasting glucose and hypertension were the strongest predictors of risk for ischemic stroke or TIA in metabolic syndrome, and HbA1c had positive associations with glycemia, TG, HDL-C, and TG/HDL-C but not LDL-C in the study of 118 older adults aged 65–95 years, of whom less than 6.5% had an HbA1c of 93% [19,33]. These data is consistent with our data in diabetic patients younger than 65 [33]. Another study evaluated the predictors of stroke stratified by age (at symptom onset: young; <50 years, older; 51–75 years, and oldest; 75 < years) using data collected over a 4-year period from 3,053 subjects with stroke. The metabolic syndrome was the only predictor among the older patients (OR 1.58) but not in the others. Although most patients were not diabetic, these types of studies should be accumulated to evaluate the effect of age on atherosclerotic diseases [34].

## Conclusions

HbA1C, LDL-C, SBP and non-HDL-C in non-elderly diabetic individuals, HDL-C in late elderly diabetic individuals and the LDL-C/HDL-C ratio in all diabetic individuals were associated with IHD in this population. HDL-C was also associated with CVA in late elderly diabetic individuals. The differences in atherosclerotic risk by age must be considered in developing individualized strategies for the prevention of atherosclerotic diseases. Because this was an observational study, we could not analyze the detailed effects of treatment, such as the effect of statins on the risk of IHD or CVA. Although this study targets Japanese, these new findings on metabolic markers in the late elderly could provide additional data for the annotation of cardiovascular risk factors in the diabetic elderly across the world.

## Abbreviations

CVA: Cerebrovascular attack; IHD: Ischemic heart disease; LDL-C: LDL-cholesterol; HDL-C: HDL-cholesterol; TG: Triglyceride; FPG: Fasting plasma glucose; HbA1C: Hemoglobin A1C; SBP: Systolic blood pressure; UKPDS: United Kingdom Prospective Diabetes Study.

All authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.

## Competing interests

The authors declare that they have no competing interests.

## Authors' contributions

TH and HN wrote the manuscript and researched the data. AA, SK, HS, HW, TO, KY, MT, KK, MN, HN, and KI contributed to the research and reviewed the manuscript. All authors read and approved the final manuscript.

## Acknowledgments

We thank the following people for contributing to this research by researching and analyzing the data: I. Sakuma (Kales Sapporo Hospital),

H. Iinuma and K. Ohashi (Tokyo University), S. Tanaka (Kyoto University), M. Yoshizumi (Hiroshima University), and H. Umegaki (Nagoya University). This work was supported in part by a grant from The Japanese Ministry of Health, Welfare and Labor. The funding body had no role in its design; in the collection, analysis, and interpretation of data; in the writing of the manuscript; or in the decision to submit the manuscript for publication.

## Author details

<sup>1</sup>Department of Geriatrics, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya, Japan. <sup>2</sup>Division of Diabetes, Metabolism and Endocrinology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan. <sup>3</sup>Osaka Saiseikai Nakatsu Hospital, Osaka, Japan. <sup>4</sup>Department of Internal Medicine, Endocrinology and Metabolism, Niigata Graduate School of Medicine, Niigata, Japan. <sup>5</sup>Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan. <sup>6</sup>Department of Geriatric Medicine, Tohoku University School of Medicine, Sendai, Japan. <sup>7</sup>Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Chiba University Hospital, Chiba, Japan. <sup>8</sup>Department of Pharmacoepidemiology, Faculty of Medicine, University of Tokyo, Tokyo, Japan. <sup>9</sup>Department of Diabetes and Metabolic Medicine, National Center for Global Health and Medicine, Tokyo, Japan. <sup>10</sup>Department of Geriatrics, Nagoya Kita Hospital, Nagoya, Japan.

Received: 10 October 2012 Accepted: 6 January 2013

Published: 9 January 2013

## References

1. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). *BMJ* 1998, **316**:823–828.
2. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *Lancet* 1998, **352**:854–865.
3. Kahn R, Robertson RM, Smith R, Eddy D: The impact of prevention on reducing the burden of cardiovascular disease. *Diabetes Care* 2008, **31**:1686–1696.
4. Sone H, Yamada N, Mizuno S, Ohashi Y, Ishibashi S, Yamazaki Y: Requirement for hypertension and hyperlipidemia medication in U.S. and Japanese patients with diabetes. *Am J Med* 2004, **117**:711–712.
5. IDF Clinical Guidelines Task Force: Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care. *Diabet Med* 2006, **23**:579–593.
6. American Diabetes Association Consensus Panel: Guidelines for computer modeling of diabetes and its complications (consensus statement). *Diabetes Care* 2004, **27**:2262–2265.
7. Hata Y, Mabuchi H, Saito Y, Itakura H, Egusa G, Ito H, Teramoto T, Tsumura M, Tada N, Oikawa S, Yamada N, Yamashita S, Sakuma N, Sasaki J, working committee on JAS Guideline for Diagnosis and Treatment of Hyperlipidemias: Report of the Japan Atherosclerosis Society (JAS) guideline for diagnosis and treatment of hyperlipidemia in Japanese adults. *J Atheroscler Thromb* 2002, **9**:1–27.
8. Fruchart JC, Nierman MC, Stroes ES, Kastelein JJ, Duriez P: New risk factors for atherosclerosis and patient risk assessment. *Circulation* 2004, **109**:1115–1119.
9. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin J, Farzadfar F, Khang YH, Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA, Ezzati M, on behalf of the Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose): 2011 National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. *Lancet* 2011, **378**:31–40.
10. Neville SE, Boye KS, Montgomery WS, Iwamoto K, Okamura M, Hayes RP: 2009 Diabetes in Japan: a review of disease burden and approaches to treatment. *Diabetes Metab Res Rev* 2009, **25**:705–716.
11. Japanese Research of Cholesterol and Diabetes Mellitus (Japan CDM: UMIN Clinical Trials Registry. 2004 ID of this investigation UMIN00000516 Japan CDM [article online]; 2004. Available from <https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&recptno=R000000624&type=summary&language=E>.

12. Announcement on the current status of Japan's Social Security System from Japan Ministry of Health, Labour and Welfare. 2010, [http://www.mhlw.go.jp/english/social\\_security/kaikaku\\_1.html](http://www.mhlw.go.jp/english/social_security/kaikaku_1.html).
13. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: **10-year follow-up of intensive glucose control in type 2 diabetes.** *N Engl J Med* 2008, **359**:1577–1589.
14. Zhang P, Imai K: **The relationship between age and healthcare expenditure among persons with diabetes mellitus.** *Expert Opin Pharmacother* 2007, **8**:49–57.
15. Hornick T, Aron DC: **Preventing and managing diabetic complications in elderly patients.** *Cleve Clin J Med* 2007, **75**:153–158.
16. Sone H, Mizuno S, Ohashi Y, Yamada N: **Type 2 diabetes prevalence in Asian subjects.** *Diabetes Care* 2004, **27**:1251–1252.
17. Doi Y, Ninomiya T, Hata J, Fukuhara M, Yonemoto K, Iwase M, Iida M, Kiyohara Y: **Impact of glucose tolerance status on development of ischemic stroke and coronary heart disease in a general Japanese population: the Hisayama study.** *Stroke* 2010, **41**:203–209.
18. Béjot Y, Giroud M: **Stroke in diabetic patients.** *Diabetes Metab*. 2010, **36**:S84–87.
19. Koren-Morag N, Goldbourt U, Tanne D: **Relation between the metabolic syndrome and ischemic stroke or transient ischemic attack: a prospective cohort study in patients with atherosclerotic cardiovascular disease.** *Stroke*. 2005, **36**:1366–71.
20. Radermecker RP, Scheen AJ: **Management of blood glucose in patients with stroke.** *Diabetes Metab* 2010, **36**:S94–99.
21. Windler E, Schöffauer M, Zyriax BC: **The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease.** *Diab Vasc Dis Res* 2007, **4**:136–142.
22. Valensi P, Pariès J, Brulport-Cerisier V, Torremocha F, Sachs RN, Vanzetto G, Cossou E, Lormeau B, Attali JR, Maréchaud R, Estour B, Halimi S: **Predictive value of silent myocardial ischemia for cardiac events in diabetic patients: influence of age in a French multicenter study.** *Diabetes Care* 2005, **28**:2722–2727.
23. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG, PROSPER study group: **Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial.** *Lancet* 2002, **360**:1623–1630.
24. Heart Protection Study Collaborative Group: **2002 MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial.** *Lancet* 2002, **360**:7–22.
25. Sever PS, Poulter NR, Dahlöf B, Wedel H, Collins R, Beevers G, Caulfield M, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J: **Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial—lipid-lowering arm (ASCOT-LLA).** *Diabetes Care* 2005, **28**:1151–1157.
26. Davis TM, Ting R, Best JD, Donoghoe MW, Drury PL, Sullivan DR, Jenkins AJ, O'Connell RL, Whiting MJ, Glasziou PP, Simes RJ, Kesäniemi YA, GebSKI VJ, Scott RS, Keech AC: **2011 Fenofibrate Intervention and Event Lowering in Diabetes Study investigators. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study.** *Diabetologia* 2011, **54**:280–290.
27. Gudbjörnsdóttir S, Eliasson B, Eeg-Olofsson K, Zethelius B, Cederholm J: **National Diabetes Register (NDR). Additive effects of glycaemia and dyslipidaemia on risk of cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register.** *Diabetologia* 2011, **54**:2544–51.
28. Fukuda Y, Miura S, Tsuchiya Y, Inoue-Sumi Y, Kubota K, Takamiya Y, Kuwano T, Ohishi H, Ike A, Mori K, Yanagi D, Nishikawa H, Shirai K, Saku K, Urata H: **Lower frequency of non-target lesion intervention in post-successful percutaneous coronary intervention patients with an LDL to HDL cholesterol ratio below 1.5.** *Int J Cardiol* 2011, **149**:120–2.
29. DeGoma EM, DeGoma RL, Rader DJ: **Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches.** *J Am Coll Cardiol* 2008, **51**:2199–2211.
30. Ramjee V, Sperling LS, Jacobson TA: **Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification: do the math.** *J Am Coll Cardiol* 2011, **58**:457–463.
31. Marshall SM, Flyvbjerg A: **Prevention and early detection of vascular complications of diabetes.** *BMJ* 2006, **333**:475–480.
32. Funami J, Hayashi T, Nomura H, Ding QF, Ishitsuka-Watanabe A, Matsui-Hirai H, Ina K, Zhang J, Yu ZY, Iguchi A: **Clinical factors such as B-type natriuretic peptide link to factor VII, endothelial NO synthase and estrogen receptor alpha polymorphism in elderly women.** *Life Sci* 2009, **85**:316–21.
33. Martins RA, Jones JG, Cumming SP, Coelho e Silva MJ, Teixeira AM, Veríssimo MT: **Glycated hemoglobin and associated risk factors in older adults.** *Cardiovascular Diabetology* 2012, **11**:13.
34. Bang OY, Saver JL, Liebeskind DS, Lee PH, Sheen SS, Yoon SR, Yun SW, Kim GM, Chung CS, Lee KH, Ovbiagele B: **Age-Distinct Predictors of Symptomatic Cervicocephalic Atherosclerosis.** *Cerebrovasc Dis* 2009, **27**:13–21.

doi:10.1186/1475-2840-12-10

**Cite this article as:** Hayashi et al.: Metabolic predictors of ischemic heart disease and cerebrovascular attack in elderly diabetic individuals: difference in risk by age. *Cardiovascular Diabetology* 2013 **12**:10.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)



ORIGINAL ARTICLE: EPIDEMIOLOGY,  
CLINICAL PRACTICE AND HEALTH**Importance of high-density lipoprotein cholesterol levels in elderly diabetic individuals with type IIb dyslipidemia: A 2-year survey of cardiovascular events**

Koichiro Ina,<sup>1</sup> Toshio Hayashi,<sup>1</sup> Atsushi Araki,<sup>3</sup> Seinosuke Kawashima,<sup>6</sup> Hirohito Sone,<sup>7</sup> Hiroshi Watanabe,<sup>8</sup> Takashi Ohru,<sup>9</sup> Koutaro Yokote,<sup>10</sup> Minoru Takemoto,<sup>10</sup> Kiyoshi Kubota,<sup>4</sup> Mitsuhiro Noda,<sup>5</sup> Hiroshi Noto,<sup>5</sup> Qun-Fang Ding,<sup>11</sup> Jie Zhang,<sup>12</sup> Ze-Yun Yu,<sup>13</sup> Byung-Koo Yoon,<sup>14</sup> Hideki Nomura,<sup>1,2</sup> and Masafumi Kuzuya,<sup>1</sup> on Behalf of Japan CDM Group

<sup>1</sup>Department of Geriatrics, Nagoya University Graduate School of Medicine, <sup>2</sup>Department of Geriatrics, Nagoya Kita Hospital, Nagoya, <sup>3</sup>Division of Diabetes, Metabolism and Endocrinology, Tokyo Metropolitan Geriatric Hospital, <sup>4</sup>Department of Pharmacoepidemiology, Faculty of Medicine, University of Tokyo, <sup>5</sup>Department of Diabetes and Metabolic Medicine, National Center for Global Health and Medicine, Tokyo, <sup>6</sup>Osaka Saiseikai Nakatsu Hospital, Osaka, <sup>7</sup>Department of Internal Medicine, Endocrinology and Metabolism, Niigata Graduate School of Medicine, Niigata, <sup>8</sup>Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, <sup>9</sup>Department of Geriatric Medicine, Tohoku University, School of Medicine, Sendai, <sup>10</sup>Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Chiba University Hospital, Chiba, Japan; <sup>11</sup>Department of Geriatrics, West China Hospital of Sichuan University, Chengdu, <sup>12</sup>Yunnan Provincial Institute of Medical Information, <sup>13</sup>Yunnan Provincial Chinese Medicine Hospital, Kunming, China; and <sup>14</sup>Department of Obstetrics and Gynecology, Samsung Medical Center, Seoul, Korea

**Aim:** The risk factors for ischemic heart disease (IHD) or cerebrovascular accident (CVA) in elderly diabetic individuals with type IIb dyslipidemia are not fully known. Therefore, we investigated the relationship between lipid levels and IHD and CVA in diabetic individuals with type IIb dyslipidemia.

**Method:** The Japan Cholesterol and Diabetes Mellitus Study is a prospective cohort study of 4014 type 2 diabetic patients (1936 women; age  $67.4 \pm 9.5$  years). The primary end-points were the onset of IHD or CVA. Lipid and glucose levels, and other factors were investigated in relation to the occurrence of IHD or CVA. A total of 462 participants were included in the group of patients with type IIb dyslipidemia.

**Results:** The 462 diabetic participants with type IIb dyslipidemia were divided into those who were aged <65 years, 65–74 years and >75 years ( $n = 168, 190$  and  $104$ , respectively). High-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol/HDL-C were significantly associated with the risk of cardiovascular events in diabetic individuals with type IIb dyslipidemia who were aged <65 years, and HDL-C and diastolic blood pressure was significantly associated with cardiovascular events in patients aged 65–74 years. Non-HDL-C was not significantly associated with the risk of cardiovascular events. Multiple regression analysis showed that lower HDL-C was significantly associated with the risk of cardiovascular events in diabetic individuals with type IIb dyslipidemia who were aged <65 years and 65–74 years.

**Conclusions:** Lower HDL-C was an important risk factor for cardiovascular events in diabetic individuals with type IIb dyslipidemia who were aged <75 years. *Geriatr Gerontol Int* 2013; ●●: ●●–●●.

**Keywords:** cerebrovascular accident, elderly type 2 diabetes, high-density lipoprotein cholesterol, ischemic heart disease, type IIb dyslipidemia.

## Introduction

Investigators in Western countries have reported that patients with both hypercholesterolemia and type 2 diabetes have a higher risk of coronary events than patients with hypercholesterolemia alone.<sup>1</sup> The incidence of ischemic heart diseases (IHD) and cerebrovascular

Accepted for publication 1 September 2013.

Correspondence: Dr Toshio Hayashi MD PhD, Department of Geriatrics, Nagoya University Graduate School of Medicine, Tsuruma-cho 65, Showa-ku, Nagoya 466-8550, Japan. Email: hayashi@med.nagoya-u.ac.jp

accident (CVA) in patients with type 2 diabetes is reported to be high in Japan.<sup>2</sup> However, risk factors for IHD or CVA in elderly diabetic individuals with hypercholesterolemia are not fully known.

Many lines of evidence show that low-density lipoprotein cholesterol (LDL-C) is an important risk factor for cardiovascular disease (CVD; CVD = IHD + CVA),<sup>3,4</sup> but it is still debatable whether plasma triglyceride (TG) levels are associated with the occurrence of CVD. However, recent reports have shown that plasma TG levels are an independent risk factor for coronary artery disease (CAD).<sup>3,5-8</sup> In addition, non-fasting TG levels have been shown to be associated with CAD and stroke.<sup>3,9,10</sup> Despite the accumulating evidence against LDL-C and TG, few reports have addressed the effect of type IIb dyslipidemia on cardiovascular disease. We considered the fact that elevated LDL-C and TG along with an increase in atherogenic lipoproteins, such as small and dense LDL, are found in type IIb dyslipidemia, and that this type of dyslipidemia is often associated with type 2 diabetes. It is important to note that when investigating diabetic individuals with type IIb dyslipidemia, there is a synergistic effect of type 2 diabetes and dyslipidemia. This effect might pose a larger risk factor for CVD, but few reports have addressed this association.

Few data were available for the elderly diabetic individuals with type IIb dyslipidemia.<sup>3</sup> Therefore, it is worthwhile to analyze the data from the Japan Cholesterol and Diabetes Mellitus investigation (Japan-CDM), which is a nationwide observational cohort study of a large number of diabetic individuals who were treated in clinical practice. It was designed to assess the relationship between lipid levels and the incidence of CVD in Japanese diabetic individuals.<sup>11,12</sup> We investigated the relationship between lipid levels, IHD and CVA in diabetic individuals with type IIb dyslipidemia in the present study.

## Methods

### Data source

The Japan Cholesterol and Diabetes Mellitus Study is a single-center prospective cohort study comprising 4014 Japanese diabetic individuals on a consecutive outpatient basis who were recruited between September 2004 and March 2005 (1936 women; age  $67.4 \pm 9.5$  years [range 35–83 years]) from 40 Japanese hospitals. Patients with coronary artery disease, which was defined as previous myocardial infarction, coronary intervention or confirmed angina pectoris and recent stroke, who had been admitted within the past 24 months were excluded. Follow-up information was available for 98.2% and 92.3% of patients enrolled in the first and second years, respectively. Patients were divided

into those who were aged <65 years, 65–74 years and <75 years ( $n = 1267$ , 1731 and 1016, respectively). The primary end-points were onset of IHD or CVA. Plasma lipid, glucose, glycated hemoglobin (National Glycohemoglobin Standardization Program) and other relevant levels were measured annually. Lipid and glucose levels, and other factors were investigated in relation to occurrence of IHD or CVA.<sup>11,12</sup>

From this study, we investigated patients with type IIb dyslipidemia. Patients with type IIb dyslipidemia were defined by having both TG  $\geq 150$  and LDL-C  $\geq 120$ . A total of 462 participants were included in the patient group showing type IIb dyslipidemia. The study was approved by institutional review boards and by the safety monitoring board. All events were confirmed annually by the organizing committee. The guidelines of the Japan Atherosclerosis Society (2002), stating that LDL-C should be <120 mg/dL and high-density lipoprotein cholesterol (HDL-C) >40 mg/dL in diabetic individuals, and the American Diabetes Association criteria for diagnosis of type 2 diabetes were used.

### Statistical analysis

Results are presented as means  $\pm$  SD. All statistical analyses were carried out using JMP software (SAS Institute, Cary, NC, USA). Incidences were analyzed in relation to risk factors. Univariate and multiple logistic regression analysis were used. We included both SBP and DBP in the same multivariable model, because systolic hypertension is very often observed in the elderly, and those variables did not show a strong correlation in the present study ( $r = 0.48$ ). Values of  $P < 0.05$  were considered significant.


## Results

The characteristics of the 462 participants are shown in Table 1. The mean age was  $67.4 \pm 9.5$  years, and 52.2% of participants used antihyperlipidemic agents. The 462 participants with type IIb dyslipidemia were divided into those who were aged <65 years, 65–74 years and <75 years ( $n = 168$ , 190 and 104, respectively). IHD and CVA occurred in 1.6 and 1.4% of participants, respectively, over a 2-year study period. The occurrence of IHD and CVA in participants with type IIb dyslipidemia was 2.4 and 1.7%, respectively. Participants with type IIb dyslipidemia made up a higher proportion of occurrence of cardiovascular events (Fig. 1). The relationship between IHD or CVA and background factors, such as LDL-C levels, in each age-group was analyzed by univariate logistic regression. Lower HDL-C was significantly associated with a risk of cardiovascular events in diabetic individuals with type IIb dyslipidemia aged <65 years and 65–74 years (Fig. 2a). Higher diastolic blood

**Table 1** Clinical background of diabetic patients with type IIb dyslipidemia

	Total	<65 years (n = 168)	65–74 years (n = 190)	≥75 years (n = 104)
Age	66.4 ± 10.6	54.8 ± 7.2	70.0 ± 2.77	78.6 ± 3.18
Sex ratio (m/f)	0.99	1.46	0.87	0.66
SBP (mmHg)	136.9 ± 18.3	133.8 ± 17.6	138.0 ± 18.4	139.9 ± 18.8
DBP (mmHg)	75.7 ± 11.3	78.5 ± 10.5	74.3 ± 11.8	73.5 ± 10.8
LDL (mg/dl)	145.6 ± 24.1	150.1 ± 26.1	145.1 ± 24.8	139.0 ± 16.7
HDL (mg/dl)	46.8 ± 11.6	47.6 ± 11.2	46.8 ± 12.8	45.7 ± 10.2
LDL-C/HDL-C	3.4 ± 2.4	3.4 ± 1.8	3.6 ± 3.3	3.2 ± 0.9
Non-HDL-C (mg/dL)	187.1 ± 29.8	194.0 ± 31.1	185.6 ± 31.6	178.7 ± 20.5
TG (mg/dL)	211.8 ± 65.1	227.5 ± 79.5	204.4 ± 55.1	199.6 ± 49.9
HbA1c (%)	7.86 ± 1.38	7.96 ± 1.54	7.74 ± 1.29	7.91 ± 1.25
Antihyperlipidemic agents (%)	(52.2)	(60.1)	(51.6)	(40.4)

DBP, diastolic blood pressure; HbA1c, glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; TG, triglycerides.



**Figure 1** A 2-year survey of cardiovascular events in each generation's type IIb dyslipidemia and of the entire study. CVA, cerebrovascular accident; IHD, ischemic heart disease.


pressure (DBP) was significantly associated with the risk of cardiovascular events in diabetic individuals with type IIb dyslipidemia who were aged 65–74 years, and LDL-C/HDL-C was significantly associated with individuals who were aged <65 years (Fig. 2a,b). Non-HDL-C was not significantly associated with the risk of cardiovascular events. We carried out multiple regression analysis. The data shown were after adjustment for age, sex, systolic blood pressure (SBP), DBP, glycated hemoglobin, plasma lipid levels and antihyperlipidemic agents. With regard to LDL-C/HDL-C, the data obtained were after adjustments for the same factors except for lipid levels. With regard to non-HDL-C, the data obtained were after adjustment for the same factors, but lipid factor is only TG. We investigated three age groups. Lower HDL-C was associated with the risk of cardiovascular events in patients who were aged <65 years and 65–74 years (Table 2).

## Discussion

Type IIb dyslipidemia is important, because it sometimes accompanies atherogenic lipid profiles, such as small dense LDL, remnant lipoprotein and low HDL cholesterol. It is also associated with type 2 diabetes mellitus, metabolic syndrome and chronic kidney disease (CKD), and most patients with familial combined hyperlipidemia (FCHL) show this phenotype.<sup>3,13–16</sup> Therefore, it is necessary to understand that patients with type IIb dyslipidemia have a high risk for CVD. The management of type IIb dyslipidemia is key to the prevention of CVD.<sup>3</sup> Therefore, we assessed the relationship between lipid levels and IHD, and CVA in diabetic individuals with type IIb dyslipidemia.

The present study showed that lower HDL-C was an important risk factor for cardiovascular events in diabetic individuals with type IIb dyslipidemia who were aged <75 years. Multiple regression analysis showed lower HDL-C levels were associated with the risk of cardiovascular events in patients who were aged <75 years. We could not show the significant association between HDL-C levels and each event. One of the reasons for this inability was the small number of type IIb patients, and the relatively short duration of observation for participants with type IIb dyslipidemia. We showed there was a significant association between HDL-C levels and total events (IHD + CVA). We could not show the significant association between non-HDL-C levels or LDL-C/HDL-C and each event by multiple regression analysis. We speculate that HDL-C was the most important risk factor for cardiovascular events in diabetic individuals with type IIb dyslipidemia. Other studies including Japanese patients with type 2 diabetes (mean age 58.2 years) showed serum TG levels were a leading predictor of coronary





**Figure 2** (a) The relationship between high-density lipoprotein (HDL-C) and diastolic blood pressure (DBP) levels, and the occurrence of events. (b) The relationship between low-density lipoprotein cholesterol (LDL-C)/HDL-C and the occurrence of events.

**Table 2** Adjusted multiple regression analyses of factors found to be significant by univariate regression analysis for cardiovascular disease, as well as major atherogenic risk factors

	<65 years ( <i>n</i> = 168)		65–74 years ( <i>n</i> = 190)		≥75 years ( <i>n</i> = 104)	
	Adjusted OR (95%CI)	<i>P</i>	Adjusted OR (95%CI)	<i>P</i>	Adjusted OR (95%CI)	<i>P</i>
Age	1.117 (0.98–1.33)	0.14	0.818 (0.57–1.13)	0.24	1.068 (0.81–1.39)	0.62
LDL-C	0.980 (0.93–1.02)	0.38	1.000 (0.95–1.03)	0.97	1.036 (0.98–1.09)	0.17
HDL-C	0.910 (0.82–0.99)	0.04*	0.900 (0.81–0.98)	0.03*	1.000 (0.92–1.09)	0.99
TG	0.996 (0.98–1.01)	0.62	1.000 (0.98–1.01)	0.94	0.996 (0.97–1.01)	0.68
HbA1c	1.030 (0.56–1.80)	0.92	0.921 (0.38–1.96)	0.84	0.803 (0.37–1.50)	0.52
SBP	1.027 (0.96–1.10)	0.45	1.008 (0.95–1.07)	0.77	0.980 (0.94–1.02)	0.33
DBP	0.992 (0.89–1.10)	0.87	1.065 (0.98–1.17)	0.14	0.975 (0.90–1.06)	0.55
LDL-C/HDL-C	1.120 (0.57–1.57)	0.57	1.161 (0.85–1.39)	0.12	1.173 (0.41–2.68)	0.72
Non-HDL-C	0.988 (0.96–1.01)	0.43	1.002 (0.96–1.03)	0.89	1.016 (0.97–1.06)	0.45

\**P* < 0.05. DBP, diastolic blood pressure; HbA1c, glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; TG, triglycerides.

heart disease (CHD), comparable with LDL-C or HDL-C.<sup>17</sup> However, our former study including all participants showed the importance of HDL-C in CVA in elderly diabetic individuals, and in IHD in middle-aged diabetic individuals.<sup>12</sup> In our previous study, lower HDL-C was significantly related to CVA in participants aged ≥65 years, and especially in those aged >75 years.<sup>12</sup> The Prospective Study of Pravastatin in the Elderly at Risk study showed that simple LDL-C control might not prevent IHD or CVA in elderly individuals.<sup>18</sup> Our former study showed the importance of HDL cholesterol in CVA in elderly diabetic individuals.<sup>12</sup>

In addition to LDL-C, HDL-C is also a key risk factor in elderly diabetic individuals.<sup>11,12</sup> Because diabetic indi-

viduals with type IIb dyslipidemia have a higher risk for CVD, the importance of HDL-C might be different than that of usual diabetic individuals. Therapeutic lifestyle changes, including those to diet and exercise, constitute the cornerstone of management in patients with type IIb dyslipidemia. Restriction of dietary cholesterol (less than 300 mg/day) and saturated fat in addition to increasing dietary fiber and plant sterols can lower LDL-C, and restriction of alcohol, sugar, saturated fat and high intake of omega-3 fatty acids can reduce serum TG.<sup>3,19</sup> Because weight reduction can further lower LDL-C and TG, and raise HDL-C levels, maximal improvement in dyslipidemia should be attempted with lifestyle intervention before prescribing lipid-lowering medications.

Risk factors for cardiovascular events appear to change with advancing age.<sup>12</sup> The importance of HDL-C is different for each age-group. The present study on diabetic individuals with type IIb dyslipidemia was small in size, so a larger study will be required. However, HDL-C might help prevent cardiovascular events diabetic patients with type IIb dyslipidemia who are aged <75 years.

With regard to antihypertensive agents, approximately half of the participants used antihypertensive agents. There were no significant relationships between CVD and antihypertensive agents. Although we did not focus on antihypertensive agents in the present study, investigation of antihypertensive agents is important, and further study will be required in the future.

In conclusion, the present study showed that lower HDL-C was an important risk factor for cardiovascular events in diabetic individuals with type IIb dyslipidemia who are aged <75 years. If HDL-C is well controlled in elderly diabetic individuals who are aged <75 years with type IIb dyslipidemia, then IHD and CVA might be decreased to the levels found in diabetic patients of middle-aged cohorts.

## Acknowledgments

This study was supported by a grant from the Japanese Ministry of Health, Welfare and Labor.

## Disclosure statement

All authors have no conflict of interests.

## References

- 1 Gotto AM. Lipid management in diabetic patients: lessons from prevention trials. *Am J Med* 2002; **112**: 19–26.
- 2 Sone H, Mizuno S, Ohashi Y, Yamada N. Type 2 diabetes prevalence in Asian subjects. *Diabetes Care* 2004; **27**: 1251–1252.
- 3 Arai H, Ishibashi S, Bujo H *et al.* Management of type IIb dyslipidemia. *J Atheroscler Thromb* 2012; **19**: 105–114.
- 4 Teramoto T, Sasaki J, Ueshima H *et al.* Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. *J Atheroscler Thromb* 2007; **14**: 45–50.
- 5 Iso H, Naito Y, Sato S *et al.* Serum triglycerides and risk of coronary heart disease among Japanese men and women. *Am J Epidemiol* 2001; **153**: 490–499.
- 6 Satoh H, Nishino T, Tomita K, Tsutsui H. Fasting triglyceride is a significant risk factor for coronary artery disease in middle-aged Japanese men. *Circ J* 2006; **70**: 227–231.
- 7 Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. *Circulation* 1998; **97**: 1029–1036.
- 8 Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. *Am J Cardiol* 1996; **77**: 1179–1184.
- 9 Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. *JAMA* 2007; **298**: 299–308.
- 10 Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting triglycerides and risk of ischemic stroke in the general population. *JAMA* 2008; **300**: 2142–2152.
- 11 Hayashi T, Kawashima S, Itoh H *et al.* Importance of lipid levels in elderly diabetic individuals: baseline characteristics and 1-year survey of cardiovascular events. *Circ J* 2008; **72**: 218–225.
- 12 Hayashi T, Kawashima S, Itoh H *et al.* Low HDL cholesterol is associated with the risk of stroke in elderly diabetic individuals: changes in the risk for atherosclerotic diseases at various ages. *Diabetes Care* 2009; **32**: 1221–1223.
- 13 Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. *Diabetes Care* 2004; **27**: 1496–1504.
- 14 Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. *Am J Physiol Renal Physiol* 2006; **290**: 262–272.
- 15 Teramoto T, Sasaki J, Ueshima H *et al.* Metabolic syndrome. *J Atheroscler Thromb* 2008; **15**: 1–5.
- 16 Gaddi A, Cicero AF, Odoo FO, Poli AA, Paoletti R. Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date. *Vasc Health Risk Manag* 2007; **3**: 877–886.
- 17 Sone H, Tanaka S, Tanaka S *et al.* Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study (JDACS). *J Clin Endocrinol Metab* 2011; **96**: 3448–3456.
- 18 Shepherd J, Blauw GJ, Murphy MB *et al.* PROspective Study of Pravastatin in the Elderly at Risk (PROSPER): a randomized controlled trial. *Lancet* 2002; **360**: 1623–1630.
- 19 Sacks FM. Dietary fat, the Mediterranean diet, and health: reports from scientific exchanges, 1998 and 2000. Introduction. *Am J Med* 2002; **113**: 1–4.

## Temporal relationship between multiple drugs and multiple events in patient reports on adverse drug reactions: findings in a pilot study in Japan

To the Editor

Patient reporting of suspected adverse drug reactions (ADRs) has been accepted as an essential component of pharmacovigilance.<sup>1,2</sup> Important signals may be detected when combined with reports from health care professionals (HCPs)<sup>3</sup> but also from “patient-only” dataset.<sup>4</sup>

In January 2011, the Health and Labour Sciences Research Grant study (“HLSRG study”) supported by the Ministry of Health, Labour and Welfare (MHLW) started a pilot study to determine whether the web-based patient reporting works in Japan. The online patient report form was linked from the main page of Pharmaceuticals and Medical Devices Agency (PMDA). To call for patient reports, a message was shown on the PMDA website and in 955 (1.7%) of about 55 000 community pharmacies, 1000 posters were displayed and 100 000 flyers were handed to patients. The study was approved by the Research Ethics Committee of Faculty of Pharmacy, Keio University.

In an interim analysis of the data collected during the first 2 months of the study, we found patients sometimes reported multiple drugs and multiple ADRs occurring at different occasions. It was often very difficult to specify the temporal relationship between the exposure to drugs and occurrence of ADRs. To improve the clarity of the temporal relationship, a revised form with multiple entry boxes for dates of ADR occurrence was used in the latter half of the study (see online Figure 1). At the end of the study, we conducted an ad hoc analysis to know whether the revised form worked as intended.

The drugs were classified by the anatomical therapeutic chemical (ATC) classification. ADRs were coded by Japanese translation of lowest level terms of the medical dictionary for regulatory activities (MedDRA) version 14.0J and converted to preferred terms (PTs) by two of authors (AH and KK) and then further checked independently by each of two psychiatric specialists (AI and TK) because many of reported ADRs were classified under the primary systemic organ class (SOC) “nervous” or “psychiatry”. The temporal relationship was classified into “clear” (clear for all drug–event combinations),

“clear/unclear” (clear for some but unclear for the other combinations) and “unclear” (unclear for all combinations) also by these two specialists. Any discrepancy between two specialists was resolved by discussion.

We also analyzed the spontaneous reports submitted by HCPs directly or through the drug company to the PMDA (“HCP reports”) and reports submitted by the “consumer or other non-health professional” through the drug company (“indirect patient reports”) during the same period using Japanese Adverse Drug Event Report database (<http://www.info.pmda.go.jp/>) and compared with “direct patient reports” in the HLSRG study.

Table 1 shows standardized differences<sup>5</sup> for demographic and other characteristics between a total of 214 direct patient reports with at least one identifiable drug and one identifiable ADR and 657 indirect patient reports as well as 34 843 HCP reports submitted to the PMDA between January and December 2011. In direct patient reports, median age of patients was 40 years old and much younger than “60’s” in other two report types. There was a difference of ADRs and drugs frequently reported between three reporter types. The 214 reports were submitted by 166 (78%) patients and 48 (22%) family members, and 16 (7%) reports had one or more over-the-counter drugs.

As shown in Table 2, during the latter half of the study period where the revised form was used, two or more dates for ADR occurrence were often reported. The ratio of the odds of the clarity (“clear” vs. others (“clear/unclear” or “unclear”)) in the latter half of the study period (51/3) to the odds in the first half (110/50) was 7.7 (95% CI:2.3–26.0). The logistic regression revealed that the “odds ratio” was 9.8 (95%CI:2.5–38.1) when adjusted for age and sex of reporters and other potentially relevant factors indicating that the revised form improved the clarity of the temporal relationship. The number of reports in the first to fourth quarter during the one-year study period was 108, 52, 30 and 24, respectively. This decrease was potentially because patients who used the internet regularly to avidly collect the information of ADRs tended to discover that the pilot study was in place and report ADRs they experienced early in the study period.

Table 1. Demographics, drugs and adverse drug reactions in spontaneous reports

Reporter type	Direct patient reports	Indirect patient reports	HCP reports	Standardized difference <sup>†</sup>
Period January 2011 – December 2011				
Number of reports	214	657	34,843	
Demographics of patients				
Sex, unknown (%)	0 (0)	29 (4.4)	719 (2.1)	−0.30, −0.21
Females (%)	111 (51.9)	340 (51.8)	16,997 (48.8)	0.002, 0.06
Age, unknown (%)	5 (2.3)	353 (53.7)	1,581 (4.5)	−1.40, −0.12
Median age (IQR) <sup>‡</sup>	40 (30, 55)	60s (40s, 70s)	60s (40s, 70s)	−0.81, −0.67
Median number per report				
ADRs (IQR)	3 (1, 5)	1 (1, 2)	1 (1, 2)	0.60, 0.63
Drugs (IQR)	2 (1, 5)	1 (1, 2)	4 (2, 8)	0.62, −0.39
Number of reports on ADR coded by a MedDRA PT with a specific primary SOC*				
Blood (%)	1 (0.5)	8 (1.2)	4,257 (12.2)	−0.08, −0.50
Eye (%)	24 (11.2)	51 (7.8)	632 (1.8)	0.12, 0.39
Gastrointestinal (%)	65 (30.4)	113 (17.2)	4,809 (13.8)	0.31, 0.41
General (%)	69 (32.2)	96 (14.6)	3,264 (9.4)	0.43, 0.59
Infections (%)	5 (2.3)	32 (4.9)	4,960 (14.2)	−0.14, −0.44
Investigations (%)	18 (8.4)	93 (14.2)	7,560 (21.7)	−0.18, −0.38
Musculoskeletal (%)	22 (10.3)	56 (8.5)	1,392 (4.0)	0.06, 0.25
Nervous (%)	91 (42.5)	212 (32.3)	5,545 (15.9)	0.21, 0.61
Psychiatric (%)	50 (23.4)	109 (16.6)	1,200 (3.4)	0.17, 0.61
Number of reports on suspect drug in a specific level-2 subgroup of ATC classification*				
Insulins (H04) (%)	0 (0)	33 (5.0)	83 (0.2)	−0.33, −0.07
Antibacterials (J01) (%)	8 (3.7)	27 (4.1)	3,075 (8.8)	−0.02, −0.21
Antivirals (J05) (%)	6 (2.8)	20 (3.0)	2,582 (7.4)	−0.01, −0.21
Vaccines (J07) (%)	4 (1.9)	33 (5.0)	1,478 (4.2)	−0.17, −0.14
Antineoplastic (L01) (%)	1 (0.5)	37 (5.6)	11,999 (34.4)	−0.30, −1.00
Psycholeptics (N05) (%)	41 (19.2)	87 (13.2)	1,949 (5.6)	0.16, 0.42
Psychoanaleptics (N06) (%)	30 (14.0)	46 (7.0)	972 (2.8)	0.23, 0.41
Ophthalmologicals (S01) (%)	1 (0.5)	22 (3.3)	1,982 (5.7)	−0.21, −0.31

IQR=interquartile range; ADR=adverse drug reaction; MedDRA=medical dictionary for regulatory activities; PT=preferred term; SOC=system organ class; ATC= anatomic therapeutic chemical.

\*Data are shown when (i) proportion of reports >10% (SOCs) or >5% (ATC level-2 subgroups) in any reporter type and (ii) ratio of proportions >2 between any two of three reporter types.

<sup>†</sup>Standardized difference between direct and indirect patient reports (left) and that between direct patient and HCP reports (right).

<sup>‡</sup>When the information on age group was given (as for all the cases in indirect patient and HCP reports), middle point (e.g. 64 years for 60s) was used to calculate the standardized mean difference.